NCT04564703: EMN26 Phase 2: Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients
NCT04617925: Phase 2: EMN 27 - Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
NCT04483739: Phase 3: EMN 24 - Isa-KRd vs KRd New Multiple Myeloma Eligible for ASCT - IsKia TRIAL
NCT04181827: Phase 3 -Cilta-cel vs Pom/Bort/Dex or Dara/Pom/Dex in relpsd. len ref MM CARTITUDE 4
NCT04131309: Phase 2: EMN 22 - Daratumumab Monotherapy in Stage 3B Light Chain (AL) Amyloidosis
NCT04133636: Phase 2 - Study of JNJ-68284528, CAR-T Therapy Directed Against BCMA in MM -CARTITUDE-2
NCT04108195: Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies - TRIMM-2
NCT04035226 - Study of Real-life Current Standards of Care in Patients With RRMM with 3 prior lines
NCT03859427: Phase 3: Once-weekly vs Twice-wkly Carfilzomib + Lenalidomide + Dex RRMM - A.R.R.O.W.2
NCT04162210: Phase 3 - Belantamab Mafodotin Vs Pomalidomide + Low-dose Dexamethasone (Pom/Dex) RRMM
NCT04126200: Phase 1/2 - Belantamab Mafodotin as Monotherapy & With Anti-cancer Rx (RRMM) (DREAMM 5)
NCT03652064 : Phase 3 - Bortezomib, Lenalidomide, Dex and +/- Daratumumab - NDMM - MMY3019 CEPHEUS
NCT03651128: Phase 3 - Study of bb2121 Vs Standard Regimens Refractory Myeloma (RRMM) (KarMMa-3)
NCT03710603: Phase 3 - Daratumumab, VELCADE, Len, Dex VS VELCADE, Len, Dex in NDMM (Perseus) EMN17
NCT03435796: Phase 2/3: Long-Term Follow-up for Participants Treated With Gene-Modified T Cells
NCT03673826: Phase 2: Carfilzomib, Lenalidomide and Dex Versus Lenalidomide and Dex High- Risk SMM
NCT03399799: Phase 1 - Talquetamab, a Humanized GPRC5D x CD3 Bis Ab - Ref MM - MonumenTAL-1
NCT03180736 : Phase 3 - EMN 14 - Pomalidomide and Dexa +/- Dara in relapsed MM - APOLLO study
NCT03151811: Phase 3- Melphalan Flufenamide (Melflufen)-Dex or Pom-dex for RRMM ref. to Len. (OCEAN)